McKesson
One Post Street
San Francisco
California
94104
United States
Tel: 415-983-8982
Fax: 415-983-8900
Website: http://www.mckesson.com/
377 articles about McKesson
-
McKesson Reports Fiscal 2022 First-Quarter Results
8/4/2021
As previously announced, the company will host a live webcast of the earnings conference call for investors , Wednesday, August 4th at 4:30 PM ET to review its financial results.
-
Total payment amounts are contingent on the number of governments that will agree to suspend their lawsuits as part of the deal.
-
Theranos founder Elizabeth Holmes is back in the courtroom for the first time in 15 months for a three-day hearing ahead of her criminal fraud trial.
-
McKesson Declares Quarterly Dividend - Apr 29, 2021
4/29/2021
The Board of Directors of McKesson Corporation yesterday declared a regular dividend of 42 cents per share of common stock.
-
McKesson Corporation to Announce Fourth Quarter Fiscal 2021 Results on May 6, 2021
4/1/2021
McKesson Corporation (NYSE: MCK) will release its fourth quarter fiscal 2021 financial results after market close on Thursday, May 6, 2021. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.
-
McKesson Expands Integrated Pharmacy Services for Specialty Clinics
3/16/2021
McKesson, Vanderbilt Health Rx Solutions to leverage collective expertise to advance the mission of health system specialty pharmacies
-
McKesson Begins Distributing the Johnson & Johnson COVID-19 Vaccine
3/1/2021
As a centralized distribution partner for the U.S. government’s COVID vaccine distribution effort, McKesson began distributing the COVID-19 vaccine received from Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
McKesson Reports Fiscal 2021 Third-Quarter Results
2/2/2021
Third-Quarter Highlights, Year-over-Year: Total revenues of $62.6 billion, reflecting 6% growth. McKesson recorded a pre-tax charge of $8.1 billion related to opioid litigation, resulting in third-quarter Loss per diluted share of ($39.03). Adjusted Earnings per diluted share of $4.60, an increase of 21%. Board of Directors authorized an additional $2.0 billion share repurchase program.
-
McKesson Declares Quarterly Dividend - Jan 28, 2021
1/28/2021
The Board of Directors of McKesson Corporation yesterday declared a regular dividend of 42 cents per share of common stock.
-
McKesson Fills Initial Government Orders for Moderna’s COVID-19 Vaccine
12/20/2020
As part of Operation Warp Speed, the U.S. government’s public-private partnership to deliver COVID-19 vaccines to Americans, and under the direction of the Centers for Disease Control and Prevention, McKesson began distributing Moderna’s COVID-19 vaccines and the ancillary supply kits needed to administer them.
-
McKesson Launches Ontada, an Oncology Technology and Insights Business Dedicated to Help Advance Cancer Research and Care
12/3/2020
McKesson Corporation announced the launch of Ontada, an oncology technology and insights business designed to support innovation, acceleration, and evidence generation to drive better outcomes for patients with cancer.
-
Michelle Snyder, Digital Health Veteran, Joins McKesson Ventures
12/1/2020
McKesson Ventures, the venture capital arm of McKesson Corporation, announces the expansion of its leadership team, welcoming Michelle Snyder as its newest investment partner.
-
Walgreens Boots Alliance and McKesson Complete the Formation of German Wholesale Joint Venture
11/2/2020
Joint venture demonstrates innovative strength of two companies with impressive and trusted healthcare heritage in the German wholesale market
-
McKesson Declares Quarterly Dividend payable on January 4, 2021
10/29/2020
The Board of Directors of McKesson Corporation yesterday declared a regular dividend of 42 cents per share of common stock.
-
Providing Care in a Pandemic and Beyond: Three Considerations for Hospital Leaders
10/27/2020
Health system and pharmacy leadership need supply chain expertise to operate in the new normal
-
McKesson’s Board of Directors Elects Linda Mantia as New Independent Director
10/19/2020
McKesson Corporation announced that the McKesson board of directors has elected Linda Mantia as an independent director and member of the board’s Audit and Governance Committees, effective Oct. 19, 2020.
-
McKesson Ventures Grows Leadership Team with New Partner Promotions
9/16/2020
McKesson Ventures, the venture capital arm of McKesson Corporation, announces the expansion of its leadership team, promoting Jennifer Carter and Carrie Hurwitz Williams to partners of McKesson Ventures.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
-
McKesson Canada Names Rebecca McKillican Chief Executive Officer
8/10/2020
McKesson Corporation announced the appointment of Rebecca McKillican as Chief Executive Officer, McKesson Canada effective immediately.
-
McKesson Reports Fiscal 2021 First-Quarter Results
8/3/2020
Increased fiscal 2021 Adjusted Earnings per diluted share guidance range to $14.70 to $15.50, from the previous range of $13.95 to $14.75.